DESOTEC Completes Acquisition of US-based Evoqua’s Carbon Reactivation and Exchange Services Business
DESOTEC, the leading provider in sustainable mobile filtration solutions in Europe, is thrilled to announce the completion of the acquisition of the carbon reactivation and exchange services business of Evoqua Water Technologies. With the integration of this US-based organization, DESOTEC broadens its horizon as it takes its first steps into a new continent.
Evoqua Water Technologies is a renowned leader in mission-critical water and wastewater treatment solutions with a wealth of expertise and a strong product portfolio in the US. The acquisition includes Evoqua’s product lines’ workforce, reactivation facilities and associated equipment in Darlington (Pennsylvania) and Parker (Arizona), and the reactivation and carbon vessel manufacturing facility in Red Bluff (California). Upon closing, DESOTEC can now provide the necessary solutions to the growing filtration demands in North America by leveraging its extensive expertise in Europe, built up over many decades.
Through a unique, flexible, and circular service concept, DESOTEC unburdens its industrial clients. With its broad range of mobile filtration solutions, the environmental services company supports its clients in their efforts to enhance the sustainability of their operations or products. In addition, it helps companies comply with environmental regulations and sustainability requirements. As of today, DESOTEC employs a total of 355 employees.
“This strategic acquisition marks the beginning of an exciting new chapter for DESOTEC as we continue our mission to better protect the planet. This landmark investment is the first step as we embark on the roll-out of our North American growth strategy and further expansion of our leading market position,” says Julie Santens, CEO of DESOTEC.
Jürgen Pinker, Senior Managing Director at Blackstone, added: “Leveraging Blackstone’s long track-record of successful corporate partnerships and experience in backing strong management teams, we are excited to continue DESOTEC’s success story, working together with Julie and the wider team to build a global partner of choice for its clients, suppliers and employees. As the need for environmental services is increasingly front and center, we believe DESOTEC is well positioned to continue to take advantage of the market opportunity and remain confident the company will continue to thrive for the long-term future.”
Revitalized brand identity
DESOTEC seizes the opportunity to reinforce its transoceanic expansion with a refreshed visual corporate identity. This encompasses updated visuals, including the logo, a new website, and the transitioning of DESOTEC’s mobile filters to the color green. The notable switch to a prominent green color amplifies DESOTEC’s commitment to environmental conservation.
This revitalized look demonstrates the evolution of the company and aims to better reflect the company’s identity, its purpose, and future aspirations. The rollout of this purpose-driven corporate identity will significantly support the future growth prospects, and will be implemented gradually over the coming months and years.
About DESOTEC
DESOTEC, founded in 1990, is the leading provider of mobile filtration solutions in Europe and is establishing this leading market position in the United States. Thanks to its unique, flexible, circular service concept and extensive expertise, DESOTEC unburdens industrial customers and helps them to make their operations or products more sustainable. DESOTEC's customer base is constantly growing thanks to a strong focus on 24/7 service and a commitment to find the best solution for and with the customer. DESOTEC has about 350 employees, who are all committed to help protect the planet by driving positive ecological change across all industries. Private equity funds managed by Blackstone acquired DESOTEC in 2021. Further information is available at www.desotec.com. Follow @desotec on LinkedIn, Facebook and Instagram.
About Blackstone
Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $991 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, Twitter, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230616787890/en/
Contact information
For media inquiries:
Global Head of Corporate Communications
Sarah Cattrysse
press@desotec.com
+32 51 246 057
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom